AP1968A - Recombinant rhabdovirus containing a heterologous fusion protein. - Google Patents

Recombinant rhabdovirus containing a heterologous fusion protein.

Info

Publication number
AP1968A
AP1968A APAP/P/2000/001852A AP2000001852A AP1968A AP 1968 A AP1968 A AP 1968A AP 2000001852 A AP2000001852 A AP 2000001852A AP 1968 A AP1968 A AP 1968A
Authority
AP
ARIPO
Prior art keywords
recombinant
fusion protein
protein
heterologous fusion
recombinant rhabdovirus
Prior art date
Application number
APAP/P/2000/001852A
Other languages
English (en)
Other versions
AP2000001852A0 (en
Inventor
Michael Whitt
Clinton S Robinson
Original Assignee
Univ Tennessee Res Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Res Corp filed Critical Univ Tennessee Res Corp
Publication of AP2000001852A0 publication Critical patent/AP2000001852A0/xx
Application granted granted Critical
Publication of AP1968A publication Critical patent/AP1968A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
APAP/P/2000/001852A 1997-12-22 1998-12-22 Recombinant rhabdovirus containing a heterologous fusion protein. AP1968A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6847297P 1997-12-22 1997-12-22
PCT/US1998/026084 WO1999032648A1 (en) 1997-12-22 1998-12-22 Recombinant rhabdovirus containing a heterologous fusion protein

Publications (2)

Publication Number Publication Date
AP2000001852A0 AP2000001852A0 (en) 2000-06-30
AP1968A true AP1968A (en) 2009-04-30

Family

ID=22082797

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2000/001852A AP1968A (en) 1997-12-22 1998-12-22 Recombinant rhabdovirus containing a heterologous fusion protein.

Country Status (14)

Country Link
US (2) US6497873B1 (enExample)
EP (1) EP1040198B1 (enExample)
JP (1) JP4544497B2 (enExample)
AP (1) AP1968A (enExample)
AT (1) ATE451466T1 (enExample)
AU (2) AU752004B2 (enExample)
BR (1) BR9814370A (enExample)
CA (1) CA2316033A1 (enExample)
DE (1) DE69841372D1 (enExample)
IL (2) IL136905A0 (enExample)
MX (1) MXPA00006184A (enExample)
NZ (1) NZ505312A (enExample)
OA (1) OA11432A (enExample)
WO (1) WO1999032648A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1716858B9 (en) * 1999-09-17 2009-08-12 Wellstat Biologics Corporation Oncolytic virus
AU2001281151A1 (en) * 2000-08-24 2002-03-04 Thomas Jefferson University Rhabdovirus-based vectors to express high levels of functional human antibodies
CA2440433A1 (en) * 2001-03-09 2002-09-19 The Regents Of The University Of California Cell culture system for synthesis of infectious hepatitis c virus
WO2003005964A2 (en) * 2001-07-11 2003-01-23 University Of Miami Recombinant vsv for the treatment of tumor cells
US7820435B2 (en) * 2002-02-06 2010-10-26 Expression Technologies Inc. De novo synthesized plasmid, methods of making and use thereof
CN1788088B (zh) 2003-03-27 2012-09-26 渥太华健康研究学会 突变的水泡性口炎病毒及其用途
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
KR20060017635A (ko) * 2003-06-05 2006-02-24 와이어쓰 홀딩스 코포레이션 베네쥬엘라 말 뇌염 바이러스 레플리콘 벡터 및파라믹소바이러스 단백질 항원을 포함하는 면역원성 조성물
AU2004250129A1 (en) 2003-06-09 2004-12-29 Wyeth Improved method for the recovery of non-segmented, negative-stranded RNA viruses from cDNA
CA2921063C (en) * 2006-09-15 2020-01-28 Ottawa Hospital Research Institute Oncolytic rhabdovirus
US8961951B2 (en) * 2007-07-06 2015-02-24 Boyce Thompson Institute For Plant Research Baculoviruses with enhanced virion production and a method for the production of baculoviruses
US8703469B2 (en) 2007-07-06 2014-04-22 Boyce Thompson Institute For Plant Research Baculoviruses with enhanced virion production and a method for the production of baculoviruses
EP2398496B1 (en) * 2009-02-20 2015-08-05 International AIDS Vaccine Initiative Vesicular stomatitis virus vectors encoding hiv env epitopes
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
US9555067B2 (en) 2012-04-18 2017-01-31 Mayo Foundation For Medical Education And Research Replication-competent vesicular stomatitis viruses
FR2996856B1 (fr) * 2012-10-15 2015-06-05 Agronomique Inst Nat Rech Novirhabdovirus recombinant utilisable comme vecteur d'antigenes
JP2020518275A (ja) * 2017-05-03 2020-06-25 バイオマリン ファーマシューティカル インコーポレイテッド 造血幹細胞の形質導入のための改善されたレンチウイルス
CN109414483B (zh) 2017-05-10 2025-10-24 制药五有限责任公司 对补体灭活作用具有抗性的用于治疗癌症的包膜病毒
CN115768784A (zh) * 2020-02-06 2023-03-07 勃林格殷格翰动物保健有限公司 用于检测抗弹状病毒抗体的多肽
CN116144608A (zh) * 2021-09-29 2023-05-23 上海行深生物科技有限公司 病毒培养方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Mebatsion et al; CELL, vol. 90 *
Schnell M.J. et al; CELL, vol 90 *
Scnhell M.J. et al; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA *

Also Published As

Publication number Publication date
JP2001526901A (ja) 2001-12-25
US20030138457A1 (en) 2003-07-24
DE69841372D1 (de) 2010-01-21
EP1040198B1 (en) 2009-12-09
NZ505312A (en) 2003-01-31
EP1040198A1 (en) 2000-10-04
IL136905A0 (en) 2001-06-14
AU752004B2 (en) 2002-09-05
ATE451466T1 (de) 2009-12-15
MXPA00006184A (es) 2003-02-11
IL136905A (en) 2007-10-31
AP2000001852A0 (en) 2000-06-30
US6497873B1 (en) 2002-12-24
WO1999032648A1 (en) 1999-07-01
CA2316033A1 (en) 1999-07-01
AU2002300207B2 (en) 2006-07-13
OA11432A (en) 2004-04-26
JP4544497B2 (ja) 2010-09-15
BR9814370A (pt) 2000-10-10
AU1905699A (en) 1999-07-12

Similar Documents

Publication Publication Date Title
AP1968A (en) Recombinant rhabdovirus containing a heterologous fusion protein.
ATE352559T1 (de) Verfahren zur verminderung der immunogenität von proteinen
GR3032058T3 (en) Embryonic stem cells for making chimeric and transgenic ungulates
MXPA03008715A (es) Reduccion de la inmunogenicidad de proteinas de fusion.
DK0662827T4 (da) Terapeutiske og diagnostiske fremgangsmåder og sammensætninger baseret på Notch-proteiner og nucleinsyrer
ATE366814T1 (de) Gl50 moleküle, sowie verwendungen derselben
AU575843B2 (en) Growth hormone releasing peptides
DE69233245D1 (de) Verfahren zur Herstellung von Peptiden
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
EP0770137A4 (en) IMPROVEMENTS IN PROTEIN PRODUCTION IN HOST CELLS
WO2024238955A3 (en) Relaxin-2 fusion protein analogs and methods of using same
WO2003018829A3 (en) 6299, a human zinc carboxypeptidase family member and uses therefor
PL363501A1 (en) Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
WO2002079222A3 (en) Fusion proteins for specific treatment of cancer and auto-immune diseases
WO2001000662A3 (en) The use of human fgh-8 polypeptides as neurotrophic agents
AU2002359572A8 (en) 15603, a human ion channel family member
WO2002077220A3 (en) Nucleic acids encoding human est1 proteins
WO2003041652A3 (en) Method of using 18080, a human serine carboxypeptidase family member